Neuropsychopharmacology

Neuropsychopharmacology is the monthly official journal of the American College of Neuropsychopharmacology, published by Springer Nature and established in 1987, covering clinical and basic science at the intersection of brain, behaviour and therapeutics, with a 2025 Journal Impact Factor of 7.6 and a first-quartile rank of 16 of 293 in psychiatry《神经精神药理学》（Neuropsychopharmacology）是（American College of Neuropsychopharmacology）的官方月刊，由（Springer Nature）出版，1987 年创刊，刊载脑、行为与治疗交汇处的临床与基础科学论文，2025 年影响因子为 7.6，在精神病学类 293 种期刊中列第 16 位，居第一四分位。

Scope

• The biological bases of normal and pathological behaviour are a primary focus, from molecular and cellular mechanisms to systems-level neuroscience正常与病理行为的生物学基础是首要关注点，从分子与细胞机制到系统层面的神经科学。
• The nature, aetiology and pathophysiology of neuropsychiatric disorders are central, including psychotic, mood, anxiety and substance-use disorders神经精神障碍的性质、病因与病理生理居于核心，包括精神病性、心境、焦虑与物质使用障碍。
• Biologically relevant aspects of epidemiology, diagnosis and treatment are within scope, linking clinical observation to mechanism与生物学相关的流行病学、诊断与治疗内容属于收稿范围，把临床观察与机制联系起来。
• The mechanisms by which psychopharmacological agents act on the central nervous system are a longstanding subject, including receptor pharmacology and circuit effects精神药物作用于中枢神经系统的机制是长期主题，包括受体药理学与神经环路效应。
• Identification of new molecular targets for the next generation of drugs is explicitly encouraged, as is translational work from animal models to human studies该刊明确鼓励寻找新一代药物的新分子靶点，也欢迎从动物模型到人体研究的转化工作。
• Original reports are preferred, while mini-reviews and perspectives are invited by the editorial office rather than submitted unsolicited该刊优先发表原创研究，小型综述与观点文章由编辑部约稿，不接受自由投稿。

History

• The journal was established in 1987 as the official publication of the American College of Neuropsychopharmacology该刊 1987 年创办，作为（American College of Neuropsychopharmacology）的官方出版物。
• Its principal editors have included J. Christian Gillin, Herbert Y. Meltzer, Charles B. Nemeroff and William A. Carlezon Jr, each shaping the journal's clinical and mechanistic balance历任主编包括（J. Christian Gillin）、（Herbert Y. Meltzer）、（Charles B. Nemeroff）与（William A. Carlezon Jr），他们共同塑造了该刊临床与机制并重的取向。
• Since 2023 the journal has been led by two co-principal editors, a structure intended to cover both preclinical and clinical neuroscience自 2023 年起，该刊改由两位共同主编主持，这一架构意在兼顾临床前与临床神经科学。
• Publication is monthly, with articles appearing online ahead of issue assignment, and the journal operates a hybrid open-access model该刊按月出版，论文先在线发表再编入期次，采用混合开放获取模式。
• The Journal Impact Factor was 7.853 in 2021 and 8.294 in 2022, then 7.1 in 2024 and 7.6 in 2025该刊影响因子 2021 年为 7.853，2022 年为 8.294，2024 年为 7.1，2025 年为 7.6。

Editors

• The co-principal editors are Lisa M. Monteggia, professor of pharmacology at Vanderbilt University, and Tony P. George, professor of psychiatry at the University of Toronto共同主编为（Vanderbilt University）药理学教授（Lisa M. Monteggia）与（University of Toronto）精神病学教授（Tony P. George）。
• Monteggia works on molecular mechanisms of antidepressant action and synaptic plasticity, while George focuses on comorbid substance use and psychotic disorders（Monteggia）研究抗抑郁药作用的分子机制与突触可塑性，（George）则聚焦共病物质使用与精神病性障碍。
• Leah Mayo serves as social media editor, and the editorial office is located in Brentwood, Tennessee, at the college's headquarters（Leah Mayo）任社交媒体编辑，编辑部设于该学会总部所在地美国田纳西州布伦特伍德。
• The journal reports a first decision within about two days and an accept decision within roughly 102 days, with online publication about 15 days after production该刊公布首次决定约需两天，录用决定约需 102 天，进入生产后约 15 天即可在线发表。
• Articles are peer reviewed by external referees, and the journal publishes a podcast series discussing selected papers with their authors论文由外部审稿人评审，该刊还制作播客节目，邀请作者讨论部分论文。
• Submissions are made through the Nature Portfolio system, and the journal attracts more than ten million article downloads a year投稿通过（Nature Portfolio）系统完成，该刊每年论文下载量超过一千万次。